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ABSTRACT
Objective This study aimed to investigate the effect of
amiloride on portal hypertension. Amiloride is known to
inhibit Na+/H+ exchangers on activated hepatic stellate
cells.
Methods Liver cirrhosis in rats was induced by bile duct
ligation (BDL) or thioacetamide (TAA) administration. The
effects of zymosan for Kupffer cell (KC) activation or
a thromboxane (TX) analogue (U46619) were tested in
isolated perfused livers of cirrhotic rats and in vivo.
Downstream mechanisms were investigated using Rho
kinase inhibitor (Y-27632) or amiloride. Acute and
chronic effects of amiloride and canrenoate on portal
pressure were compared in perfused livers and in vivo.
TXB2 efflux was measured by ELISA. The phosphorylation
state of moesin (p-moesin) as an indicator of Rho kinase
activity and expression of the thromboxane synthase
were assessed by western blot analyses. The activity of
hepatic stellate cells was analysed by western blot and
staining for a-smooth muscle actin (a-SMA).
Results In BDL rats, KC activation via zymosan
increased portal pressure. This was attenuated by the
Rho kinase inhibitor Y-27632. Increased thromboxane
efflux following zymosan infusion remained unaltered by
Y-27632. The infusion of amiloride attenuated zymosan-
and U46619-induced increases in portal perfusion
pressure. In vivo, direct administration of amiloride, but
not of canrenoate, lowered portal pressure. In TAA and
BDL rats, treatment with amiloride for 3 days reduced
basal portal pressure and KC-induced increases in portal
pressure whereas canrenoate had no effect. In livers of
amiloride-treated animals, the phosphorylation state of
moesin and the number of a-SMA positive cells were
reduced.
Conclusions Amiloride lowers portal pressure in rat liver
cirrhosis by inhibition of intrahepatic vasocontraction.
Therefore, patients with cirrhosis and portal hypertension
may benefit from amiloride therapy.
INTRODUCTION
Variceal bleeding represents a life-threatening
complication of portal hypertension in chronic liver
diseases. Mortality is, at first, closely connected to
control of acute and then of recurrent bleeding,
which occurs in up to 40% of patients.1e3 Sudden
and uncontrolled increases in portal pressure are
responsible for variceal bleeding in patients with
liver cirrhosis and portal hypertension.4 In cirrhotic
livers, impairment of the intrahepatic microcircu-
lation is the result of both structural changes and
an increased intrahepatic vascular tone.5e7
Alterations of intrahepatic vascular tone in liver
cirrhosis originate from an upregulation of vaso-
constrictors,8 including thromboxane (TX) A2,9 10
and a decrease in vasodilators.11 Activation of
Kupffer cells (KCs) results in the formation of
TXA2, which increases portal pressure.10 12e14
Postulated contractile cells in the liver are
activated hepatic stellate cells (HSCs) and
myofibroblasts.5 Contraction mechanisms of these
cells are under the control of Ca2+-dependent and
Ca2+-independent pathways. Both pathways are
upregulated in the cirrhotic liver by activation and
excessive proliferation of HSC. Ca2+-independent
pathways include activation of Rho kinase by
vasoconstrictors; these pathways lead to contrac-
tion of hepatic stellate cells and myofibroblasts.15 16
Indeed, inhibition of Rho kinase in the intrahepatic
microvasculature of cirrhotic livers causes
substantial decreases in intrahepatic vascular resis-
tance and portal pressure.17e19
Several in vivo and in vitro studies, which
focussed on the pathomechanisms of fibrogenesis,
identified the potential of the Na+/H+ exchanger
amiloride to inhibit the activity of hepatic stellate
cells.20 21 However, the effects of amiloride or other
inhibitors of Na+/H+ exchangers on increased
intrahepatic vascular resistance or on portal
hypertension in cirrhosis have not been tested. The
present study investigated the effects of amiloride
on portal pressure in rat liver cirrhosis.
MATERIALS AND METHODS
Animals
All animals were ethically treated according to the
criteria of the National Academy of Sciences
published by the National Institutes of Health and
according to legal requirements in Germany. All
animal experiments were approved by the local
government (Regierung von Oberbayern, Munich,
Germany) and were reported to the responsible
authorities every 3 months.
Induction of liver fibrosis by bile duct ligation
Male SpragueeDawley rats (180e200 g; Charles
River, Sulzfeld, Germany) were anaesthetised by
intraperitoneal pentobarbital injection (75 mg/kg
body weight (b.w.)). After a midline laparotomywas
performed, the common bile duct was ligated twice
with 3e0 silk and cut between the two ligations.10 19
Sham-operated rats were subjected to laparotomy
without bile duct ligation (BDL). Liver perfusion
withKrebseHenseleit buffer and in vivo experiments
were performed 4 weeks after the operation, as
described below. At this time, the rats had elevated
values in liver function tests (alkaline phosphatase,g-
glutamyltransferase, bilirubin, aspartate amino-
transferase and alanine aminotransferase, see table 1).
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Induction of liver cirrhosis by thioacetamide
Rats were treated with thioacetamide (TAA) for 18 weeks.22 In
brief, male SpragueeDawley rats (Charles River) between 200
and 250 g were weighed once per week. A starting dose of 0.3%
TAA was added to drinking water. If a body weight variation of
20% or more from 1 week to the next was determined, the dose
of TAA was adapted as described previously.22
In situ rat liver perfusion
Rats were anaesthetised with an intraperitoneal injection of
sodium pentobarbital (50 mg/kg b.w.). After incision of the
abdominal wall, blood was taken from the inferior vena cava
(about 3e4 ml) in order to determine serum parameters.
Subsequently, the portal vein was cannulated with an intra-
venous 14-gauge Teflon catheter, and the liver was perfused at
a constant flow rate. The inferior vena cava was cannulated via
the right atrium and ligated above the right renal vein. In all
experiments, livers were perfused with KrebseHenseleit solu-
tion (pH 7.4, 378C) in a non-recirculating fashion. The perfu-
sion buffer was gassed with a mixture of 95% O2 and 5% CO2
using an oxygenator.23 Portal perfusion pressure was monitored
continuously. The bile duct was cannulated with a poly-
ethylene tube (PE10) to monitor bile flow in both sham-oper-
ated and non-operated animals. The liver was allowed to
stabilise for 25 min before any substances were added. During
this initial 25 min stabilisation period, the criteria for liver
viability included stable perfusion pressure and lactate dehy-
drogenase (LDH) efflux rates < 5 mU/min3g liver. LDH
activity was analysed as previously reported.24 If any of the
criteria for viability were not satisfied, the sample was
discarded.
Kupffer cell activation and blockade of Rho kinase by Y-27632
KCs were activated by the infusion of cell wall particles from
Saccharomyces cerevisiae (zymosan A, n¼5). Zymosan was
prepared and infused as described previously in minutes 40e46
after starting perfusion experiments (150 mg/ml),23 25 and
combined with Y-27632 or solvent (water) from minutes 25 to
55. In control experiments, perfusion was performed only with
KrebseHenseleit buffer over 100 min (n¼5). Infusion with Y-
27632 (10 mmol/l, during minutes 25 to 55, n¼5) was used to
block Rho kinase-mediated contraction of hepatic stellate cells
and myofibroblasts.19 26
Acute amiloride effects in liver perfusion
In a further set of experiments, KC activation by zymosan
(150 mg/ml, during minute 40e46 after starting perfusion
experiments, n¼5) was combined with amiloride infusion
(100 mmol/l, minute 25 to 55, n¼5). In another set of experi-
ments, the thromboxane A2 agonist U46619 (0.1 mmol/l, minute
40 to 46, n¼5) was infused with or without amiloride
(100 mmol/l, minute 25 to 55, n¼5). The diuretic amiloride has
been shown to block hepatic stellate cells in in vivo and in vitro
studies for fibrogenesis.20
In vivo measurements of portal pressure
Body weight was determined immediately prior to each exper-
iment. Surgery (4 weeks after BDL or 18 weeks after TAA) was
begun after anaesthesia, using an intra-peritoneal injection of
sodium pentobarbital (50 mg/kg b.w.). Arterial blood pressure
was continuously monitored via a carotid catheter. Laparotomy
was performed and a PE tube (23G, 0.6330 mm) was inserted
into the ileocolic vein and advanced to the confluence of the
portal vein and splenic vein.10 27 This cannula was used for the
simultaneous infusion of zymosan and the registration of portal
pressure, as described earlier,10 27 via a transducer system (Sire-
cust 404; Siemens, Munich, Germany, and Transducer Gabarith
from Becton Dickinson, Singapore). This transducer has linearity
from <2% or 1 mm Hg and is approved for the clinical use in
humans (information from the manual supplied by Becton
Dickinson).
Acute effects of amiloride on zymosan-induced increase
of portal pressure in vivo
Four weeks after BDL, a bolus of amiloride (0.25 mg/kg b.w.)
was injected into the femoral vein 5 min before intraportal
zymosan application (3.2 mg/min, from minute 0 to 6) to
investigate the effect of amiloride on KC-dependent increase of
portal pressure (n¼7).
Acute effects of amiloride and canrenoate on basal portal
pressure in vivo
Portal pressure and systemic blood pressure were monitored
continuously over the stabilisation period of 10 min and the
following 40 min. After the stabilisation period, a bolus of
amiloride (0.1 mg/kg b.w., n¼4; 0.25 mg/kg b.w., n¼4; 0.5 mg/
kg b.w., n¼4) or canrenoate (1 mg/kg b.w., n¼4; 2.5 mg/kg b.w.,
n¼4; 5 mg/kg b.w., n¼4) was infused into the femoral vein to
delineate the potential of amiloride or canrenoate to lower basal
portal pressure.
Effects of treatment with amiloride or canrenoate for 3 days
on portal pressure
Amiloride (0.1 mg/kg b.w., n¼7), canrenoate (5 mg/kg b.w.,
n¼7) or vehicle (water) were applied by subcutaneous injection
once a day during the last 3 days of 4 weeks of BDL or 18 weeks
of TAA administration (n¼7/group). Afterwards, KCs were
activated in vivo by zymosan (intraportal application, 3.2 mg/
min, from minute 0 to 6).
Table 1 Serum parameters from normal animals, bile duct ligated (BDL) animals, thioacetamide administered (TAA) or TAA animals with amiloride
(0.1 mg/kg b. w.) or canrenoate (10 mg/kg b. w.) pre-treatment
Normal BDL TAA TAA+amiloride pre-treatment TAA+canrenoate pre-treatment
Sodium (mmol/l) 14264.2 13764.7 13866.3 13965.6 13766.4
Potassium (mmol/l) 4.260.3 4.360.8 4.160.7 4.860.5 4.560.7
Creatinine (mg/dl) 0.260.1 0.360.1 0.460.1 0.460.2 0.360.2
Bilirubin (mg/dl) 0.260.1 8.360.5+ 0.360.1 0.360.1 0.260.1
Aspartate transaminase (U/l) 4568 98617* 132612* 124618* 129615*
Alanine aminotransferase (U/l) 3465 75612y 13965y 12765y 13565y
g-Glutamyl transferase (U/l) 1.360.4 2161.7z 1861.9z 1061.5z 2161.7z
Alkaline phosphatase (U/l) 165623 172640 183640 187640 195640
Bilirubin (+p<0.05) increased only in BDL animals; AST, ALT and gGT in TAA and BDL animals (*p<0.05,yp<0.05, zp<0.05).
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Measurements of serum parameters
Serum parameters were measured by an Olympus AU2700
analyser (Olympus Germany GmbH, Hamburg), according to
standard tests based on the recommendations of the Interna-
tional Federation of Clinical Chemistry (IFCC).
ELISA
The levels of TXB2 (the stable degradation product of TXA2)
produced by the livers were quantified by measuring their
release into the perfusate. Levels of TXB2 were measured in
duplicate using an enzyme immunoassay (Assay Design, Ann
Arbour, Michigan, USA). This assay has an intra-assay coeffi-
cient of variation of 3.6%, 4.0% and 1.6% and an inter-assay
coefficient of variation of 7.6%, 3.6% and 6.2% for low, medium
and high values (data from the manual). Furthermore, the test
has a cross-reactivity <0.01% for prostaglandin D2, E2, F1a
and F2a.
Histological evaluation, staining for a-smooth muscle actin,
and TUNEL assay
Liver tissue was fixed in 4% buffered formalin, dehydrated in
graded ethanol and embedded in paraffin by standard methods.
Longitudinal sections, 4 mm thick, were stained with H&E
(haematoxylin/eosin) and Elastica van Gieson (EvG) according
to standard procedures. Immunohistochemistry was performed
using an anti-actin antibody (Millipore, Billerica, Massachusetts,
USA), dilution 1:300, and the detection system Histofine Simple
Stain MAX PO MULTI (Medac, Wesel, Germany) (n¼7 per
group). The terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate nick-end labelling (TUNEL) method
was performed using the Apop Tag Peroxidase Detection Kit
(Millipore, Schwalbach, Germany) according to the manufac-
turer ’s instructions (n¼7 per group).
Western blot analyses for phospho-moesin, total moesin,
and a-smooth muscle actin
To assess the effect of amiloride on Rho kinase activity in BDL
and TAA rats, western blot analyses for phospho-moesin (thre-
onine 558) and total moesin were performed according to
standard procedures. Additionally, the expression of the throm-
boxane synthase and the content of a-SMA were measured.
Briefly, after SDS-PAGE and blotting, proteins transferred to the
membrane were detected by incubation with primary antibodies
(anti-phospho-moesin, anti-moesin and anti-a-SMA; Santa Cruz
Biotechnology, Santa Cruz, California,USA; and anti-throm-
boxane synthase; Cayman Chemical, Ann Arbor, Michigan,
USA), followed by incubation with a horseradish peroxidase
(HRP)-conjugated secondary antibody (Santa Cruz Biotech-
nology). Bands were visualised using a chemiluminescent
detection kit (ECL Plus; Amersham Pharmacia, Uppsala,
Sweden). b-Actin was used as an internal control and detected
with an appropriate anti-b-actin antibody (Millipore, Billerica,
USA). The computed quantitative analyses were performed
with ImageJ (NIH, USA).
Drugs and reagents
Zymosan, Y-27632, amiloride and canreonate were obtained
from Sigma Aldrich (Munich, Germany). Amiloride and canre-
noate were handled in the dark as far as possible and dissolved
in water. Water was heated to below 508C to dissolve
amiloride; this was not necessary for canrenoate. U46619 was
from Cayman Chemical (Ann Arbour, USA) and dissolved in
DMSO.
Statistical analysis
All data are expressed as means6SD. Statistical analyses were
performed using ANOVA and the Student t test, where appro-
priate. A p value <0.05 was considered to be statistically
significant. Statistical preparation and analyses were performed
in collaboration with the Institute for Biometrics and Epidemi-
ology of the University of Munich (IBE, Munich, Germany).
RESULTS
KC-dependent portal pressure increase via thromboxane A2
and Rho kinase
All rats had developed ascites and portal hypertension 4 weeks
after BDL, as determined by an increase in portal pressure
measured in vivo immediately prior to the start of liver perfu-
sion. As expected, spleen weight had also increased in the rats
(1.560.2 g vs 0.460.1 g). In control experiments, portal perfu-
sion pressure was found to be constant during 100 min of liver
perfusion (figure 1A). Activation of KCs by zymosan markedly
increased portal perfusion pressure from 11.361.3 cm H2O to
24.861.7 cm H2O (figure 1A). The Rho kinase inhibitor Y-27632
significantly attenuated this zymosan-induced increase of portal
perfusion pressure about 60% (figure 1A). Activation of KCs was
paralleled by an increased efflux of TXB2, the stable degradation
product of TXA2 (figure 1B). The enhanced TXB2 efflux was not
altered by Y-27632 (figure 1B).
Attenuation of portal hypertension by amiloride
The zymosan-induced increase of portal perfusion pressure
following KC activation was reduced by infusion of amiloride by
about 50% (figure 2A) in rats with BDL-induced liver fibrosis.
Similar to zymosan, the TX analogue U46619 increased portal
perfusion pressure (figure 2A). Again, this increase was attenu-
ated by infusion of amiloride by about 50% (figure 2A). pH was
measured in the effluent perfusate, but not affected by infusion
of amiloride (data not shown). These effects were confirmed by
measurement of portal pressure in vivo. Infusion of amiloride in
vivo attenuated the acute portal pressure increase after
zymosan-induced KC activation in BDL rats (figure 2B). The
infusion of zymosan lowered systemic mean arterial pressure in
both groups (table 2).
Dose response for amiloride and canrenoate on portal pressure
in vivo
We next assessed the potential of amiloride and canrenoate to
lower basal portal pressure of BDL rats in vivo without zymosan
challenge. Similar to amiloride, canrenone has been found to
block HSC activity. Both canrenoate and spironolactone are
prodrugs of the active metabolite canrenone. Amiloride lowered
portal pressure at each dose tested (figure 3A). This amiloride-
induced decrease of portal pressure was dose-dependent (figure
3A). In contrast, canrenoate affected portal pressure only
slightly and at high doses, although this was not statistically
significant (figure 3B). Neither systemic mean arterial pressure
(table 2) nor heart rate was affected by either compound in any
treatment group (data not shown).
Effects of amiloride and canrenoate treatment for 3 days in
BDL-induced and TAA-induced cirrhosis
Using the animal model of BDL- and TAA-induced cirrhosis, we
performed studies to examine the mechanisms underlying the
effects of amiloride. All rats had developed the histological
picture of liver cirrhosis, elevated values in liver function test
(table 1), increased spleen weight (1.560.2 vs 0.460.1 g) and
ascites. In vivo, the basal portal pressure was higher in rats
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4 weeks after BDL or with TAA-induced liver cirrhosis than in
non-cirrhotic control rats. Amiloride administration for 3 days
reduced both basal portal pressure and zymosan-induced
maximal portal pressure in BDL and TAA rats by about 30%
(figure 4A,B). In contrast to amiloride, the treatment of TAA rats
with canrenoate did not affect basal portal pressure or zymosan-
induced maximal portal pressure (figure 4A,B). Portal pressure
values at the end of the experiments were comparable to initial
values (figure 4C). Heart rate (data not shown), systemic mean
arterial pressure (table 2) and grade of cirrhosis (data not shown)
were not affected by treatment with amiloride or canrenoate.
Western blot analyses showed a reduced content of phosphor-
ylated moesin (p-moesin) in livers of amiloride-treated BDL and
TAA rats compared to livers of vehicle-treated BDL or TAA rats,
while the content of total moesin (t-moesin) was not affected
(figure 5A,B). This observation was confirmed by quantification
of western blots (figure 5A,B). In contrast, the expression of
thromboxane synthase was not influenced by amiloride treat-
ment (figure 5C) in TAA-induced cirrhosis. To evaluate the effect
of amiloride treatment on activity of the hepatic stellate cells,
immunohistological stainings of a-SMA were performed (figure
6A). Analysis of these stainings showed a decrease in the number
of a-SMA positive cells in the amiloride-treated group of TAA
rats compared to the group of TAA rats with vehicle adminis-
tration (figure 6A). These findings were substantiated by
western blot analyses which showed a reduced content of a-
SMA following amiloride treatment (figure 6B). To investigate
whether processes of apoptosis were involved in the reduction of
the a-SMA positive cells, a TUNEL assay has been performed.
The analysis of this staining demonstrated that there was no
difference in the number of apoptotic cells between vehicle-
treated and amiloride-treated animals (figure 7).
DISCUSSION
This study describes the effects and underlying mechanisms of
amiloride on portal hypertension in different animal models of
30
0 20 40 60 80 100
Perfusion Time (min)
0
10
15
20
25
H 
mc( erusser
P noisufre
P latro
P
2
)
O
ZY
Y-27632
control
Zy
Zy + Y-27632
*
#
* *
*
*
#
#
*
0 20 40 60 80 100
Perfusion Time (min)
0
1000
2000
3000
4000
B
X
T
2
)revil g x ni
m/ gp(
Zy
Y-27632
5000
Zy
Zy + Y-27632
A
B
Figure 1 Rho kinase-dependent increase in portal perfusion pressure
following Kupffer cell (KC) activation. Data are expressed as mean6SD.
(A) KC activation by zymosan A (, Zy, 150 mg/ml, minute 40 to 46,
n¼5) 4 weeks after bile duct ligation (BDL) increased portal perfusion
pressure (*p<0.05) compared to controls (o, n¼5). Additional infusion
of Rho kinase inhibitor Y-27632 (-, 10 mmol/l, minute 25 to 55, n¼5)
attenuated this portal perfusion pressure increase (#p<0.05). (B) The
portal perfusion pressure increase by zymosan was parallelled by efflux
of thromboxane B2 (, TXB2, n¼5), the stable degradation product of
TXA2. Y-27632 (o, 10 mmol/l, minute 25 to 55, n¼5) did not alter efflux
of TXB2 into perfusate.
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Figure 2 Amiloride attenuates portal perfusion pressure increase.
Data are expressed as mean6SD. These experiments were performed
4 weeks after BDL. (A) Liver perfusion experiments. Maximal increase of
portal perfusion pressure following zymosan A (150 mg/ml, minute 40 to
46, n¼5) was reduced by amiloride infusion (100 mmol/l, minute 25 to
55, n¼5). The thromboxane A2 analogue U46619 (0.1 mmol/l, minute 40
to 46, n¼5) increased portal perfusion pressure, which was lowered
by amiloride infusion (100 mmol/l, minute 25 to 55, n¼5, **p<0.0006).
(B) In vivo experiments. Bolus infusion of amiloride into the femoral vein
(, 0.25 mg/kg b.w., minute 5, n¼5, #p<0.05) attenuated portal
pressure increase in vivo following Kupffer cell activation by zymosan
(-, Zy intraportal, 3.2 mg/min, minute 0e6, n¼7, *p<0.05). Control
experiments with a stabilisation period of 10 min and an observation
period of 40 min afterwards showed almost no change in portal pressure
(:, n¼4).
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cirrhosis. We observed a reduction in intrahepatic vascular
resistance and portal pressure by amiloride. Although amiloride
can be applied for the treatment of cirrhosis, the current study
is, to our knowledge, the first investigation of the effects of
amiloride on portal hypertension. Most important among our
findings were that (1) KC activation increased the portal pres-
sure via TXA2 and the consecutive intrahepatic vasoconstriction
by Rho kinase; (2) blockade of hepatic stellate cells by amiloride
lowered portal pressure dose-dependently and was more effec-
tive than canrenoate; and (3) amiloride reduced both basal portal
pressure and acute KC-dependent portal pressure increases in rat
liver cirrhosis These results were obtained using in situ perfused
livers and confirmed by in vivo studies in two different animal
models of cirrhosis. The diagnosis of cirrhosis in the BDL and
TAA rats was made based on serum parameters, the presence
of ascites, changes in liver histology and elevated portal pressure
in vivo.
Kupffer cell activation and inhibition of Rho kinase
Our initial set of experiments demonstrated that the activation
of KCs by infusion of zymosan increased portal perfusion pres-
sure in livers 4 weeks after BDL. This confirmed findings in our
previous studies.10 Interestingly, the addition of the Rho kinase
inhibitor Y-27632 prevented this KC-dependent increase in
portal perfusion pressure. Rho kinase has been described as an
important mediator of vasoconstriction in hepatic stellate cells
and intrahepatic myofibroblasts.15 19 Kupffer cell activation
resulted in thromboxane production, which was not influenced
by the Rho kinase inhibitor, while portal pressure was signifi-
cantly reduced by the Rho kinase inhibitor. Indeed, Rho kinase
in intrahepatic microvasculature may represent an attractive
target for therapies of portal hypertension. Infusion of a Rho
kinase inhibitor results in dramatic decreases of mean arterial
pressure and systemic vascular resistance15 18. Therefore, alter-
natives to block intrahepatic vasoconstriction are needed.
Reduction of portal pressure by amiloride
Amiloride is routinely used as a diuretic and has been shown to
prevent fibrogenesis effectively in vitro and in vivo.20 The in
vitro data suggest that amiloride inhibited activation of the
Na+/H+ exchanger on isolated hepatic stellate cells. Besides
fibrogenesis, activated hepatic stellate cells mediate contraction
of the intrahepatic vasculature. We therefore tested the
hypothesis that amiloride attenuates intrahepatic vascular
resistance and portal pressure due to decreased HSC contraction
in intrahepatic microvasculature by KC-derived vasoconstric-
tors. Indeed, amiloride attenuated increases of portal perfusion
pressure following direct KC activation by zymosan or admin-
istration of the thromboxane analogue U46619. We assume that
the effects of amiloride in our study can be attributed to the
inhibition of Na+/H+ exchangers, because unspecific actions (eg,
inhibition of the adrenergic system) require higher doses than
used here.28 Furthermore, pH remained unchanged in effluent
Table 2 Mean arterial pressure during in vivo portal pressure
measurements
Mean arterial pressure (mm Hg) minute L5 minute 6 minute 40
BDL
Amiloride 0.1 mg/kg b.w. 109612 115614 114612
Amiloride 0.25 mg/kg b.w. 117615 110612 117614
Amiloride 0.5 mg/kg b.w. 103615 105610 107611
Canrenoate 2.5 mg/kg b.w. 105614 98612 104610
Canrenoate 5 mg/kg b.w. 108612 105614 108612
Canrenoate 10 mg/kg b.w. 102614 110612 112614
Zymosan 109612 84615 67612y
Zymosan + amiloride 0.25 mg/kg b.w. 104615 81614 64612y
TAA
Zymosan 124612 115611 8569*
Zymosan + canrenoate pre-treatment 121614 11068 7867*
Zymosan + amiloride pre-treatment 115611 9768 7565*
The mean arterial pressure did not differ between bile duct ligated (BDL) and thioacetamide
administered animals (TAA). Mean arterial pressure decreased by Kupffer cell activation via
zymosan (150 mg/ml) from minute 0 to 6 in the BDL animals with or without immediate
amiloride treatement (*p<0.05). Mean arterial pressure also decreased in the TAA animals
by zymosan (150 mg/ml) administration (yp<0.05), but the mean arterial pressure was not
influenced by canrenoate (10 mg/kg b.w.) or amiloride (0.1 mg/kg b.w.) pre-treatment
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Figure 3 Doseeresponse curves for acute effects of amiloride and
canrenoate in vivo. Data are expressed as mean6SD. These
experiments were performed 4 weeks after bile duct ligation (BDL). (A)
Bolus infusion of amiloride in three different doses (minute 0, each n¼4)
into the femoral vein showed a reduction of portal pressure in vivo after
40 min compared to portal pressure at the end of the stabilisation period
in the same animals (minute 1). (B) In contrast, the bolus infusion of
canrenoate in three different concentrations (minute 0, each n¼4) into
the femoral vein showed a slight, but not significant, reduction of portal
pressure in vivo after 40 min compared to portal pressure at the end of
the stabilisation period (minute 1).
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perfusate following amiloride infusion during in situ liver
perfusion, although amiloride is an inhibitor of the Na+/H+
channel. Therefore, observed effects cannot be ascribed to
alterations in intrahepatic pH, and induced changes of pH were
probably balanced by other mechanisms. These effects of
amiloride on acute portal perfusion pressure increases were also
investigated in vivo, where we determined that infusion of
amiloride lowered the zymosan-induced increase of portal pres-
sure. However, the infusion of zymosan resulted in a dramatic
decrease in mean arterial blood pressure. This effect can be
deduced to a general activation of macrophages in the body. The
activation of macrophages, for example via TLR2 and TLR4 in
the whole body, leads to a sepsis-like syndrome which has been
described earlier.10 Although the blood pressure decreased, the
portal pressure still increased. Altogether, the in vivo experi-
ments supported data obtained from isolated perfused livers.
Effects of canrenoate and amiloride on portal pressure
It has been described that canrenone, the active metabolite of
canrenoate and spironolactone, may inhibit the activity of
hepatic stellate cells21 and lower portal pressure.29 30 Therefore,
we compared dose-dependent effects of canrenoate and
amiloride on portal pressure in vivo. Three different doses were
tested for each drug: a dose over the upper limit for therapeutic
administration in humans (amiloride 0.5 mg/kg b.w., canrenoate
5 mg/kg b.w.), a high but feasible dose for treatment in humans
(amiloride 0.25 mg/kg b.w., canrenoate 2.5 mg/kg b.w.) and
a generally recommended dose for diuretic treatment in humans
(amiloride 0.1 mg/kg b.w., canrenoate 1 mg/kg b.w.). Amiloride
reduced portal pressure at all doses. In contrast, portal pressure
decreased only slightly but not significantly by the administra-
tion of canrenoate at any dose. A short-term treatment over
3 days confirmed the data of the dose response curve. The
amiloride treatment over 3 days lowered both the basal and
maximal portal pressure in vivo following KC activation, but
canrenoate altered neither basal nor maximal portal pressure.
This is, to our knowledge, the first time that the effects of
canrenoate and amiloride on portal pressure have been tested in
a model of bile duct ligation or of TAA-induced cirrhosis. The
effects of amiloride occurred in both animal models and seemed,
therefore, to be independent of the aetiology of the underlying
experimental liver disease.
Mechanisms involved in reduction of portal pressure by amiloride
In addition to our functional experiments, we performed
investigations at a molecular level to identify mechanisms that
may underlie the reduction of intrahepatic vascular resistance by
amiloride. Due to the treatment period of 3 days, any anti-
fibrotic effects expected in long-term treatment21 may be
excluded in the present study. This was confirmed by Elastica
van Giesson staining showing no effect on the extent of fibrosis.
The western blot analyses showed that the content of phos-
phorylated moesin was reduced by amiloride treatment, while
the expression of total moesin was not altered. This indicates
a decrease of Rho kinase activity by amiloride. Therefore, we
speculated that the decrease of intrahepatic vascular resistance
in response to amiloride is related to reduced activation of
contraction-mediating Rho kinase in cells of intrahepatic
Figure 4 Amiloride but not
canrenoate treatment for 3 days
reduced portal pressure in vivo. Data
are expressed as mean6SD. Amiloride
(0.1 mg/kg b.w., n¼7 per group),
canrenoate (5 mg/kg b.w., n¼7 per
group) or the vehicle for both (water,
n¼7 per group) was given
subcutaneously during the last 3 days
of bile duct ligation (BDL) for 4 weeks
or thioacetamide (TAA) administration
period of 18 weeks. (A) Basal portal
pressure (minute 5) was much higher
in BDL and TAA animals than in control
animals (*p<0.0001) and was reduced
by amiloride pre-treatment (+p<0.006,
#p<0.005) compared to animals
treated with the vehicle. In contrast,
canrenoate pre-treatment did not alter
portal pressure in vivo in TAA animals.
(B) Maximal portal pressure following
Kupffer cell activation by zymosan (Zy
intraportal, 3.2 mg/min, minute 0e6, +
+p<0.002, ##p<0.004) was
attenuated by amiloride pre-treatment
in comparison to the vehicle group.
Canrenoate did not alter maximal portal
pressure. (C) At the end of the
experiments (minute 40), portal
pressure decreased to close to initial
values (minute 5) and was still
reduced in the amiloride pre-treatment
group.
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microvasculature. To further investigate involvement of the
hepatic stellate cells, we performed immunohistochemical
stainings of liver sections for a-SMA. This is widely used as
marker for activated hepatic stellate cells.31e34 The staining for
a-SMA indicated a reduced number of activated hepatic stellate
cells in the cirrhotic livers after treatment with amiloride.
Western blot analyses confirmed that there was a decrease in the
a-SMA content by amiloride pre-treatment. However, the
TUNEL assay showed no difference for apoptotic cells in vehicle-
and amiloride-treated animals. Therefore the reduced a-SMA
content in this experimental setting rather suggests a reduced
activity status of the cells with contractile elements. The
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Figure 5 Hepatic phospho-moesin levels and thromboxane synthase expression. (A and B) Effects of amiloride on contractile cells. Phosphorylation
of moesin reflects the activity of contraction-mediating Rho kinase in cells such as hepatic stellate cells and myofibroblasts. Treatment of BDL or TAA
rats with amiloride for 3 days resulted in decreased hepatic phospho-moesin levels (*p<0.002, **p<0.008), reflecting reduced activity of Rho kinase
in the intrahepatic vasculature. Shown are representative western blots and quantification of all experiments (mean6SD, n¼7 per group). (C) Effects of
amiloride on thromboxane synthase expression. The major hepatic cell type expressing thromboxane synthase are Kupffer cells. Treatment of TAA rats
with amiloride for 3 days was without effect on hepatic expression of thromboxane synthase. Shown are representative western blots and
quantification of all experiments (mean6SD, n¼7 per group).
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expression of the thromboxane synthase was not altered by
amiloride treatment. In the liver, thromboxane synthase is
mainly expressed by KCs.10 12 35e37 This suggests that amiloride
reduced intrahepatic vascular resistance via an HSC-dependent
mechanism. In addition other mechanisms seem possible.
A decreased contraction of myofibroblasts surrounding vascular
shunts in cirrhotic septa could be involved in amiloride-induced
portal pressure decreases. Major changes in the plasma volume
can be excluded due to an almost unaltered mean arterial blood
pressure although minor alterations of the plasma volume are
feasible. The cardiac output was not measured in these experi-
ments, so that an effect of amiloride on the portal inflow can not
be excluded. However, a short treatment period of 3 days or
acute application was sufficient to reduce intrahepatic vascular
resistance and portal pressure by actions on intrahepatic vaso-
constrictor-responsiveness, but without antifibrotic effects.
Clinical considerations
In the present study, amiloride was administered subcutane-
ously and intravenously. In clinical practice, amiloride is taken
orally. After oral application, amiloride is absorbed in the gut by
about 50e70%, but accumulates by repeated doses. Therefore
we would expect that the effect is still clear when amiloride is
administered orally.
Previously, amiloride was investigated in patients with liver
cirrhosis for treatment of ascites, but not yet for portal hyper-
tension. It has been shown that amiloride for treatment of
ascites is effective for patients with normal plasma aldosterone
level.38 Because of the frequency of elevated plasma aldosterone
levels in patients with liver cirrhosis, spironolactone seems to be
more effective than amiloride to treat ascites in patients with
liver cirrhosis.39
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Figure 6 Immunohistochemical staining and western blot analyses of liver sections for a-smooth muscle actin (a-SMA). (A) Liver sections of
solvent- and amiloride-treated thioacetamide (TAA) rats were stained for a-SMA. Treatment of TAA rats with amiloride for 3 days resulted in reduced
a-SMA-positive cells. Shown are representative microscopic pictures from solvent- and amiloride-treated TAA rats, and quantification of all stained
sections (n¼7 per group). (B) These findings were confirmed by western blot analyses which showed a reduced content of a-SMA in amiloride-treated
animals (n¼7 per group).
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Figure 7 TUNEL assay for detection of apoptotic cells. TUNEL assay
was performed as indicated and showed no difference in apoptotic cells
for vehicle- or amiloride-treated cells. Shown are representative
microscopic pictures from solvent- and amiloride-treated TAA rats, and
quantification of all stained sections (n¼7 per group).
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The efficacy of spironolocatone or potassium canreonate to
lower portal pressure has been investigated in different stud-
ies.40e42 In one clinical study, spironolactone reduced HVPG by
about 18% in a small group, which included three Child A
patients, while no effect was observed in six Child B patients.40
The portal pressure decrease observed in the present study was
performed in TAA and BDL rats with advanced cirrhosis. This
suggests that amiloride may be more effective than spirono-
lactoe or canreonate in advanced cirrhosis. This is confirmed by
another clinical study,41 where the appearance or progression of
oesophageal varices in pre-ascitic cirrhosis was not reduced by
potassium canrenoate. In a preliminary study, combination
therapy of nadolol plus spironolactone did not increase the
efficacy of nadolol alone in prophylaxis of first variceal
bleeding.43 In our experimental study, canrenoate was associated
with a slight but not significant decrease in portal pressure. The
effect in our study was slightly less pronounced than in earlier
experimental studies.29 30
Treatment with amiloride over 3 days in our experimental
study lowered the portal pressure by attenuation of intra-
hepatic responsiveness to vasoconstrictors. Intrahepatic vaso-
constriction is also dependent on cirrhosis formation which was
not influenced by the treatment over 3 days in the present
study. Previous studies observed antifibrogenic effects by
amiloride in vivo and in vitro20 21 and by canrenone in vitro.21
Therefore both, canrenone and amiloride could influence fibrosis
progression, but this was beyond the scope of the present study.
In fact, the present study demonstrated that amiloride lowered
portal pressure by short term treatment via attenuation of
intrahepatic vasocontraction in addition to the antifibrogenic
effect which has been described previously by long-term
treatment.20
CONCLUSIONS
In conclusion, amiloride is effective in lowering portal pressure
while canrenoate had limited potential to lower portal pressure
in rat liver cirrhosis. This suggests that amiloride may benefit
patients with liver cirrhosis and portal hypertension by lowering
portal pressure, in addition to its diuretic effect.
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Editor’s quiz: GI snapshot
ANSWER
From the question on page 807
Pathological evaluation of the resected tumour revealed
a tubular adenoma with mild glandular dysplasia (figure 1).
Small bowel adenomas are classified histologically as tubular,
tubulovillous or villous.1 They have more frequently been
described in the duodenum than in the jejunum and the ileum.2
They may develop as single or multiple lesions, both sessile and
pedunculated. Haemorrhage, obstruction and intussusception
are the most common complications.2 Rarely, they may be
associated with malignant degeneration.1 Preoperative diagnosis
of this tumour is difficult. DBE and CE are useful modalities in
detecting small bowel tumours, including adenomas. Small
bowel adenomas should be removed because of the risk of
malignancy or complication; conventionally this meant surgical
resection.3 Endoscopic polypectomy is an alternative method
despite a high risk of complications such as haemorrhage or
perforation.4 Endoloop-assisted polypectomy of large gastroin-
testinal tumours, mostly lipomas, has been reported to be safe
and efficacious.5 To date, this is the first case of a large jejunal
adenoma that was successfully treated with an endoloop-
assisted polypectomy using DBE.
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Figure 1 Pathological examination of the resected tumour confirmed
the diagnosis of a tubular adenoma with mild glandular dysplasia
(H&E, 3 20).
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